Skip to main content
    • Aa
    • Aa

The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment

  • Jae Hoon Moon (a1), Hyung Jun Kim (a2), Ae Hee Yang (a2), Hyun Min Kim (a1), Byung-Wan Lee (a1), Eun Seok Kang (a1), Hyun Chul Lee (a1) and Bong Soo Cha (a1) (a2)
  • DOI:
  • Published online: 01 November 2011

Thiazolidinediones, such as rosiglitazone or pioglitazone, are anti-diabetic agents that have been expected to show a beneficial effect in Alzheimer's disease (AD) because of their anti-inflammatory effect. However, these agents have failed to show a significant beneficial effect on AD in recent clinical trials. Here, we suggest that low-dose rosiglitazone treatment, and not the conventional doses, has an amyloid β (Aβ)-clearing effect by increasing LRP1, an Aβ outward transporter in the blood–brain barrier. Rosiglitazone up-regulated LRP1 mRNA and protein expression and LRP1 promoter activity in human brain microvascular endothelial cells (HBMECs). Aβ uptake through LRP1 in HBMECs was also increased by rosiglitazone. This increase in LRP1 and Aβ uptake was observed in up to 10 nm rosiglitazone concentration. At concentrations above 20 nm rosiglitazone, the LRP1 expression and Aβ uptake in HBMECs were not altered. The possible mechanism of this unusual dose response is discussed. This study suggests a new therapeutic application of thiazolidinediones for AD at a much lower dose than the doses used for diabetes treatment.

Corresponding author
Address for correspondence: B. S. Cha, M.D., Ph.D., Prof., Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, Korea. Tel.: +82-2-2228-1962Fax: +82-2-393-6884Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

K Akter , EA Lanza , SA Martin , N Myronyuk , (2011). Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? British Journal of Clinical Pharmacology 71, 365376.

C Ballard , S Gauthier , A Corbett , C Brayne , (2011). Alzheimer's disease. Lancet 377, 10191031.

KA Bates , G Verdile , QX Li , D Ames , (2009). Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Molecular Psychiatry 14, 469486.

R Deane , Z Wu , A Sagare , J Davis , (2004). LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333344.

A Gauthier , G Vassiliou , F Benoist , R McPherson (2003). Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 278, 1194511953.

DS Geldmacher , T Fritsch , MJ McClendon , G Landreth (2011). A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Archives of Neurology 68, 4550.

M Gold , C Alderton , M Zvartau-Hind , S Egginton , (2010). Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders 30, 131146.

JJ Goto , RE Tanzi (2002). The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's A beta generation: development of a cell-based model system. Journal of Molecular Neuroscience 19, 3741.

S Hauser , G Adelmant , P Sarraf , HM Wright , (2000). Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. Journal of Biological Chemistry 275, 1852718533.

J Herz , DK Strickland (2001). LRP: a multifunctional scavenger and signaling receptor. Journal of Clinical Investigation 108, 779784.

G Landreth , Q Jiang , S Mandrekar , M Heneka (2008). PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5, 481489.

KG Mawuenyega , W Sigurdson , V Ovod , L Munsell , (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.

OR Monro , JB Mackic , S Yamada , MB Segal , (2002). Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiology of Aging 23, 405412.

M Niemi , JT Backman , M Granfors , J Laitila , (2003). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46, 13191323.

P Riederer , J Bartl , G Laux , E Grunblatt (2011). Diabetes type II: a risk factor for depression-Parkinson-Alzheimer? Neurotoxicity Research 19, 253265.

A Sagare , R Deane , RD Bell , B Johnson , (2007). Clearance of amyloid-beta by circulating lipoprotein receptors. Nature Medicine 13, 10291031.

M Shibata , S Yamada , SR Kumar , M Calero , (2000). Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 106, 14891499.

M Shinohara , N Sato , H Kurinami , D Takeuchi , (2010). Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. Journal of Biological Chemistry 285, 2209122102.

M Ueno , T Nakagawa , B Wu , M Onodera , (2010). Transporters in the brain endothelial barrier. Current Medicinal Chemistry 17, 11251138.

O Wirths , G Multhaup , TA Bayer (2004). A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide–the first step of a fatal cascade. Journal of Neurochemistry 91, 513520.

BV Zlokovic , R Deane , AP Sagare , RD Bell , (2010). Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. Journal of Neurochemistry 115, 10771089.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary Image

Moon Supplementary Image
Moon Supplementary Image

 Unknown (382 KB)
382 KB